Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
-
Published:2022-05
Issue:
Volume:167
Page:1-12
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Kudo MasatoshiORCID, Finn Richard S., Edeline JulienORCID, Cattan Stéphane, Ogasawara Sadahisa, Palmer Daniel H., Verslype Chris, Zagonel Vittorina, Fartoux Laetitia, Vogel Arndt, Sarker Debashis, Verset Gontran, Chan Stephen L., Knox Jennifer, Daniele BrunoORCID, Yau ThomasORCID, Gurary Ellen B., Siegel Abby B., Wang Anran, Cheng Ann-Lii, Zhu Andrew X.
Subject
Cancer Research,Oncology
Reference17 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018 2. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study;Fitzmaurice;JAMA Oncol,2017 3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008 4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018 5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|